Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. - Wikidata - wikimedia - TriplyDB

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.

http://www.wikidata.org/entity/Q34532636

about

Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221 Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2 Childhood acute lymphoblastic leukemia: Integrating genomics into therapy Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL Hematopoietic stem cell transplantation in infants.Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Hematopoietic stem cell transplantation for leukemia Developmentally induced Mll1 loss reveals defects in postnatal haematopoiesis Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners The MLL recombinome of acute leukemias in 2013.H2AX: functional roles and potential applications.A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells.A case of therapy-related acute lymphoblastic leukemia with t(11;19)(q23;p13.3) and MLL/MLLT1 gene rearrangement Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia.Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia The biological and clinical significance of MLL abnormalities in haematological malignancies.Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia Does hematopoietic stem cell transplantation benefit infants with acute leukemia?Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease MicroRNA-126-mediated control of cell fate in B-cell myeloid progenitors as a potential alternative to transcriptional factors.Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.Epigenetic regulation in adult stem cells and cancers.An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas.The MLL recombinome of acute leukemias in 2017.ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.

P2860

Q24624389-F6ABE351-B49B-4BEB-A275-3D5915C744A5 Q24643476-2C114470-CBC0-4113-B9D9-416BD9DFC9A7 Q24685514-2C747438-0049-4E59-88C0-69C07E98F6C6 Q28080463-BCA6550A-B400-4E63-BB9F-588AE34F5D9F Q28087637-BD7509E9-65A3-4A8F-91D4-48FBF56893FB Q28475897-B7DF7FD2-34CF-455C-8627-2E17A0DB8818 Q33418697-78A2A85E-7ECA-40E8-B49F-A886D836D36C Q33433407-31D0D91A-85CD-49B4-B1B2-291C0D006BD9 Q34034180-948A576D-9775-427C-A015-B310BA52AC8C Q34195379-21B467ED-9BD8-49D0-98DA-174B51D37AF1 Q34601806-BFCEA3F6-81D9-4281-9076-D8FF9FE6B968 Q34620470-99C604D3-A026-47C8-9228-C16C1446AAC2 Q34651113-7AFE2D0B-A1F7-4775-A3D3-094F42A442A1 Q34982397-C4454BA4-427B-45E7-BE1F-3577DCF773A1 Q34987995-F479A68C-86B8-4014-9ABF-68A54249913A Q35034197-8B4D74AE-DBD2-42A1-8B9C-94178DA547EF Q35616078-F252F7B6-C9DD-41E5-AD05-9560D2EFDF13 Q35712192-86A5A439-DD54-48AF-A3DA-5C0928FFA7B1 Q35847465-DB6A6982-2038-49C4-B292-FAF1407F0B50 Q35850044-70F25833-B95B-49A9-B4C5-9D542CA266D6 Q35854955-D0290F9D-A17D-4A77-A1BA-ED88C1E6A66F Q35940027-12EBDC4C-0B0F-48FB-8399-A347DDCFF580 Q36311738-8CC88566-2B9B-4F31-8503-18E10B9C5ADF Q36318780-BEBBE84C-726C-4D2D-98A4-6A15ADF4F809 Q36420748-B024D1C1-806E-44CE-98F8-05E658DA5036 Q36437006-219D4563-A9AD-4D22-8FAC-528EC99773DE Q36488188-F67775CC-B5AE-4F5F-87DB-EA72C45DF66C Q36602853-2D8BB9FC-5674-411B-99E6-7FF32B5536B9 Q36735211-37600131-3F40-4451-B613-674A23D0BA94 Q37104006-4740DB7C-6865-4912-94D2-22BBAFF5F5E6 Q37165093-5324C309-D104-4DD6-B7DA-287E75AC096F Q37306997-79673F29-0E03-4FC9-89E4-2A2CF18C2537 Q37317957-E7033C34-10DA-4ACE-9EE1-FE3C1F276CBF Q37366481-45EE7523-4EA1-4F81-9A96-D4756F084966 Q37401608-C7525F38-24CC-48A7-96A0-6703C25225D4 Q37436345-C6F9298E-D997-4145-A2DB-03A7CF66B367 Q37633585-030CF586-E140-461F-9A5A-C812CD98B73D Q37896168-F6AA9D97-70BF-4155-BD0E-8C3AC76A935C Q38681972-A8C47A2B-7113-464B-9D1F-BB14F01C2FEC Q38700338-45100CBB-DF5B-4C0F-A3B4-205D86020727

P2860

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.

http://www.wikidata.org/entity/Q34532636

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@ast

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@en

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@nl

type

label

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@ast

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@en

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@nl

prefLabel

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@ast

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@en

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@nl

P1433

Q34532636-BD3EB2D4-12D0-402F-ABD9-1A9BB3994A5F

P1476

Q34532636-6D0FAF2F-F459-43D7-90D5-AF0D3C2602A1

P2093

Q34532636-051D48FA-A71E-41BC-BAA5-EBCD1288F1EB

Q34532636-069A4AEA-6266-4CF5-B68F-C113DEA32982

Q34532636-17912FAB-C77E-43FB-835A-DC98A47DF0C3

Q34532636-1C6DC7F4-2863-4579-87DB-08D2D1A18D0B

Q34532636-1D44416F-EAA8-4C82-8132-37A5AF254B08

Q34532636-1FB1B1FC-D3F0-4CB6-AFC2-70F089C60462

Q34532636-4336B7EE-D28E-4EC0-A714-739065824E39

Q34532636-4C2046E9-5233-41DA-80C1-E3AB22F57668

Q34532636-546D7519-F6DF-4F12-A649-BD7C2B92197D

Q34532636-5A1C297C-9F55-4B83-9833-76E59188424C

P2860

Q34532636-0CA0F61C-0911-4CA8-A578-EA02DD313FDE

Q34532636-0CF5E575-3DB0-45A1-96D0-9A5B1EBEA91D

Q34532636-44F16747-67B2-45D9-AD4F-DEF0D4EA5DE9

Q34532636-4D17F838-A2F2-4058-9578-B1310976B584

Q34532636-75BD2042-289E-4A3B-947E-623F837ABFF8

Q34532636-90F36D81-16D4-4198-8CF0-0F282C52BE6A

Q34532636-95359C45-AD4E-4C6D-BA0D-DB7613B150F8

Q34532636-A99882B0-DE1B-4500-9EBA-0B7155BF76E8

Q34532636-A9DF84A1-D54B-43DE-8AAC-3E86513633D2

Q34532636-D42230AD-443A-4F79-A7D8-A1B503FC3775

P2888

Q34532636-200AE138-E789-47FA-BA10-D810DA624900

P304

Q34532636-32D3A4F6-21BE-4823-AB94-E659A429D4AC

P31

Q34532636-5042CB48-2D01-42C8-BE02-06ED2A60ECEB

P356

Q34532636-C0A5A80A-B1BE-472D-A5DA-598AECEA2DA8

P433

Q34532636-B75707BC-56FC-42BC-BBC2-D9B545334662

P478

Q34532636-C9A2B1BE-606E-4F7C-ACCE-AE3709A3BBD3

P577

Q34532636-44917489-9CA1-4710-A397-E3360C7FA801

P5875

Q34532636-11D6239C-D141-4E52-AA4C-7789CB77CF15

P6179

Q34532636-1777FC56-7FF8-4009-BA0A-A8F1637DA90E

P698

Q34532636-4B1F5E16-5A1F-4751-9A52-1C29AAB93AAC

P921

Q34532636-0AC1B954-6C68-4A20-9AE8-7D959D59E7CF

P356

P1433

P1476

Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.

@en

P2093

Baruchel A

http://www.w3.org/2001/XMLSchema#string

Biondi A

http://www.w3.org/2001/XMLSchema#string

Boyett JM

http://www.w3.org/2001/XMLSchema#string

Camitta B

http://www.w3.org/2001/XMLSchema#string

Carroll A

http://www.w3.org/2001/XMLSchema#string

Chessells JM

http://www.w3.org/2001/XMLSchema#string

Eden OB

http://www.w3.org/2001/XMLSchema#string

Evans WE

http://www.w3.org/2001/XMLSchema#string

Gadner H

http://www.w3.org/2001/XMLSchema#string

Gaynon PS

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation.

Childhood acute lymphoblastic leukaemia--current status and future perspectives.

11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.

Acute leukemias with the t(4;11)(q21;q23).

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.

Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999.

P2888

P304

700-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2402883

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10815459

http://www.w3.org/2001/XMLSchema#string

P6179

1010107921

http://www.w3.org/2001/XMLSchema#string

P698

12682627

http://www.w3.org/2001/XMLSchema#string

P921